Cognitive impairment in psychiatric patients (we included subjects with schizophrenia/schizo-affective disorder, major depressive disorder and obsessive compulsive disorder Mental and Behavioural Disorders Cognitive impairment in psychiatric patients (we included subjects with schizophrenia/schizo-affective disorder, major depressive disorder and obsessive compulsive disorder
Conditions
Interventions
Participants are randomly assigned to either treatment as usual (TAU) or the intervention plus TAU. All recruited participants are randomly assigned after completion of screening and baseline measurem
Sponsors
MyCognition
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Ability to give informed consent 2. Where participants are of legal childhood age, consent will also be obtained from one of the participant’s parents. Both the parent and participant will be required to sign the consent form in such a case. It will be the investigator’s responsibility to determine whether a participant of legal childhood age has the capacity to consent to the study. 3. Age 16 - 55 years old 4. DSM-IV-TR diagnosis of schizophrenia/schizoaffective disorder, obsessive compulsive disorder or major depressive disorder 5. Fluent in Dutch 6. Clinically stable
Exclusion criteria
Exclusion criteria: 1. High risk of suicide (score of 2 or more on HAM-D suicide item) 2. Unstable medical disorder 3. Having met the criteria for a substance abuse disorder in the last three months (measured by the MINI-plus) 4. History of a clinically significant abnormality of the neurological system (including dementia and other cognitive disorders or significant head injury) or any history of seizure (excluding febrile seizure) 5. Premorbid IQ < 70
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive functioning is measured using CANTAB and MyCQ at baseline and 12 weeks after the intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cognitive functioning is asssessed using the MyCQ at week 4 and week 8 2. Severity of symptoms is measured using PANSS for psychotic patients, YBOCS for OCD patients and IDS for depressed patients at baseline and 12 weeks 3. Blood marker abnormalities is measured using blood collection at baseline 4. Electro-encephalogram (EEG) is measured using the P300 and Mismatch negativity and resting state at baseline and 12 weeks 5. Level of functioning is measured using GAF Score at baseline and 12 weeks 6. Cortisol level is measured using hair analysis at baseline and 12 weeks | — |
Countries
Netherlands
Contacts
Public ContactAnna Domen
Outcome results
None listed